28.08.2013 • NewsDede WillamsPKN Orlenphenol

PKN Orlen to Expand Phenol Output to 200,000 t after 2017

Poland's PKN Orlen, which claims to be the largest oil and petrochemicals producer in the former East Bloc, has announced plans to widen its production capacity for phenol and acetone.

The company said output of phenol an important starting material for a variety of chemical processes, in particular for producing the polyamide precursor caprolactam — will be lifted from currently about 50,000 t/y to 200,000 t/y, with the first expansion stage due to be completed in 2017. Production of acetone will be increased to more than 100,000 t/y from about 50,000 t/y.

At present, around 70% of Polish demand for phenol is met by imports - mostly from Germany, Belgium and Finland, and PKN said it wants to increase its share of the market against international competition.

Altogether, the petrochemicals giant intends to spend 2.7 billion zloty (some €638 million) on a comprehensive development plan to upgrade its production technology, with an eye to saving energy and feedstock input. Up to Aug. 23, it surveyed capabilities of Polish and international contractors to design and build new facilities and will invite tenders through its Connect online procurement platform.

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.